Strong initial responses in 4 of 6 patients after many standard drugs had failed ...

Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare.

(NASDAQ: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases, today announced the ...

Researchers from the Icahn School of Medicine at Mount Sinai have discovered a promising new way to improve CAR-T cell ...

A new study reveals a possible way to make CAR T-cell therapy more durable and effective by targeting a single ...

Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing ...

The cost of CAR T-cell therapy means that the highly effective cancer treatment is unavailable in many parts of the world.

Sequencing CAR T-cell therapy versus bispecific antibodies in myeloma increasingly hinges on MRD depth, transplant candidacy, ...

B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most common childhood cancer, making up 35% of pediatric cancer cases, but it ...

Recently published T-cell Malignancies Market Insights report includes a comprehensive understanding of current treatment ...